Nickel sulfate (NiSO4)

Nickel sulfate is an inorganic compound primarily recognized in clinical medicine as a potent hapten and a leading cause of allergic contact dermatitis (StatPearls, 2023). It is not a therapeutic target in the traditional sense; instead, it functions as an exogenous agent that binds to endogenous proteins to form an antigenic complex (PubMed, PMID: 30058741). This complex subsequently activates T-lymphocytes, triggering a Type IV hypersensitivity reaction in sensitized individuals (StatPearls, 2023). While nickel is an essential cofactor for certain bacterial enzymes like urease, it has no known physiological function in human metabolism (PubChem, CID 24586). Chronic exposure to nickel sulfate, particularly through inhalation in industrial settings, is linked to an increased risk of lung and nasal cancers (IARC, 2012). Consequently, it is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC, 2012). Management of nickel-related conditions involves avoidance of exposure and the use of topical immunosuppressants to manage inflammation (NIH, 2022). In rare cases of systemic nickel toxicity, chelating agents such as disulfiram or EDTA may be employed to facilitate metal excretion (PubChem, CID 24586). Diagnostic identification of sensitivity is typically performed via patch testing, which remains the gold standard for confirming nickel allergy (StatPearls, 2023).

Other names

Nickel(II) sulfateNickelous sulfateSulfuric acid, nickel(2+) saltNickel monosulfateRetgersite

Nickel sulfate acts as a hapten by binding to endogenous proteins, such as serum albumin, to create a neoantigen that is processed by antigen-presenting cells and presented to T-lymphocytes, inducing a Type IV hypersensitivity reaction (StatPearls, 2023). In cases of systemic toxicity, chelating agents like disulfiram or EDTA provide coordinating ligands that bind the nickel ion, forming stable, water-soluble complexes that are subsequently excreted by the kidneys (PubChem, CID 24586).